Long‐term benefit of IGHV mutated patients in a real‐life multicenter cohort of FCR‐treated chronic lymphocytic leukemiaRiccardo Moia, Gianluca Gaïdano, Riccardo Dondolin et al.|Hematological Oncology|2022Cited by 4
Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohortAndrea Serafin, Andrea Visentin, Alessandro Cellini et al.|Blood Advances|2025Cited by 3
Rethinking the feasibility and safety of venetoclax-obinutuzumab in chronic lymphocytic leukemia: non-traditional factors may play a role in clinical practiceAnna Maria Frustaci, Lara Crucitti, Andrea Galitzia et al.|Haematologica|2025Cited by 2
Real-World Venetoclax-Obinutuzumab in 232 Treatment Naive CLL Patients: Feasibility and TolerabilityAlessandra Tedeschi, Luca Laurenti, Andrea Galitzia et al.|Blood|2023Cited by 1
<i>CAT</i> rs1001179 Single Nucleotide Polymorphism Identifies an Aggressive Clinical Behavior in Chronic Lymphocytic LeukemiaMarilisa Galasso, Maria Teresa Scupoli, Vittoria Salaorni et al.|Hematological Oncology|2024Cited by 1